Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: An experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence

Vaccine

Volumn 27, Issue 48, 2009, Pages 6770-6776

  Hung, Hui Fang ^a   Chen, Tony Hsiu Hsi ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Cost effectiveness analysis; Disease transmission; Hepatitis B; Vertical

Indexed keywords

HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN;

ARTICLE; CHRONIC HEPATITIS; COHORT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DEATH; DRUG COST; DRUG EFFICACY; HEALTH CARE SYSTEM; HEALTH PROGRAM; HEPATITIS B; HUMAN; INFANT; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MONTE CARLO METHOD; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SEROPREVALENCE; TAIWAN; VACCINATION; VIRUS CARRIER; VIRUS IMMUNITY;

CARCINOMA, HEPATOCELLULAR; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION PROGRAMS; INFANT; INFANT, NEWBORN; MARKOV CHAINS; MASS VACCINATION; MODELS, ECONOMIC; MONTE CARLO METHOD; PREVALENCE; QUALITY-ADJUSTED LIFE YEARS; TAIWAN;

EID: 70350565499     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.08.082     Document Type: Article

References (67)

1. Kao J.H., and Chen D.S. Global control of hepatitis B virus infection. Lancet Infect Dis 2 (2002) 395-403
2. Chung D.C., Ko Y.C., Chen C.J., Wu C.C., and Wang Z.H. Epidemiological study on hepatitis B virus infection among five ethnic groups in Pingtung County, Taiwan. Taiwan yi xue hui za zhi 86 (1987) 497-504
3. Chen C.J., Yu M.W., and Liaw Y.F. Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol 12 (1997) S294-308
4. Margolis H.S., Coleman P.J., Brown R.E., Mast E.E., Sheingold S.H., and Arevalo J.A. Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations. JAMA 274 (1995) 1201-1208
5. Chen H.L., Chang M.H., Ni Y.H., Hsu H.Y., Lee P.I., Lee C.Y., et al. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. JAMA 276 (1996) 906-908
6. Lee C.L., Hsieh K.S., and Ko Y.C. Trends in the incidence of hepatocellular carcinoma in boys and girls in Taiwan after large-scale hepatitis B vaccination. Cancer Epidemiol Biomarkers Prev 12 (2003) 57-59
7. Chen H.L., Chang C.J., Kong M.S., Huang F.C., Lee H.C., Lin C.C., et al. Pediatric fulminant hepatic failure in endemic areas of hepatitis B infection: 15 years after universal hepatitis B vaccination. Hepatology 30 (2004) 257-264
8. Chen H.L., Chang C.J., Kong M.S., Huang F.C., Lee H.C., Lin C.C., et al. Pediatric fulminant hepatic failure in endemic areas of hepatitis B infection: 15 years after universal hepatitis B vaccination. Hepatology 39 (2004) 58-63
9. Tilson L., Thornton L., O'Flanagan D., Johnson H., and Barry M. Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation. Eur J Public Health 18 (2008) 275-282
10. Hutton D.W., Tan D., So S.K., and Brandeau M.L. Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B. Ann Intern Med 147 (2007) 460-469
11. Garuz R., Torrea J.L., Arnal J.M., Forcen T., Trinxet C., Anton F., et al. Vaccination against hepatitis B virus in Spain: a cost-effectiveness analysis. Vaccine 15 (1997) 1652-1660
12. Kim S.Y., Salomon J.A., and Goldie S.J. Economic evaluation of hepatitis B vaccination in low-income countries: using cost-effectiveness affordability curves. Bull World Health Organ 85 (2007) 833-842
13. Lin D.B., Wang H.M., Lee Y.L., Ling U.P., Changlai S.P., and Chen C.J. Immune status in preschool children born after mass hepatitis B vaccination program in Taiwan. Vaccine 16 (1998) 1683-1687
14. Lin Y.C., Chang M.H., Ni Y.H., Hsu H.Y., and Chen D.S. Long-term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan. J Infect Dis 187 (2003) 134-138
15. Ni Y.H., Chang M.H., Huang L.M., Chen H.L., Hsu H.Y., Chiu T.Y., et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med 135 (2001) 796-800
16. Beasley R.P., Hwang L.Y., Lee G.C., Lan C.C., Roan C.H., Huang F.Y., et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 2 (1983) 1099-1102
17. Edmunds W.J., Medley G.F., Nokes D.J., O'Callaghan C.J., Whittle H.C., and Hall A.J. Epidemiological patterns of hepatitis B virus (HBV) in highly endemic areas. Epidemiol Infect 117 (1996) 313-325
18. del Canho R., Grosheide P.M., Mazel J.A., Heijtink R.A., Hop W.C., Gerards L.J., et al. Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982-1992: protective efficacy and long-term immunogenicity. Vaccine 15 (1997) 1624-1630
19. Ip H.M., Lelie P.N., Wong V.C., Kuhns M.C., and Reesink H.W. Prevention of hepatitis B virus carrier state in infants according to maternal serum levels of HBV DNA. Lancet 1 (1989) 406-410
20. Lee S.D., Lo K.J., Wu J.C., Tsai Y.T., Wang J.Y., and Ting L.P. Prevention of maternal-infant hepatitis B virus transmission by immunization: the role of serum hepatitis B virus DNA. Hepatology 30 (1986) 257-264
21. Lee S.D., Lo K.J., Wu J.C., Tsai Y.T., Wang J.Y., and Ting L.P. Prevention of maternal-infant hepatitis B virus transmission by immunization: the role of serum hepatitis B virus DNA. Hepatology 6 (1986) 369-373
22. Edmunds W.J., Medley G.F., Nokes D.J., Hall A.J., and Whittle H.C. The influence of age on the development of the hepatitis B carrier state. Proc R Soc Lond B 253 (1993) 197-201
23. Goldstein S.T., Zhou F., Hadler S.C., Bell B.P., Mast E.E., and Margolis H.S. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 34 (2005) 1329-1339
24. Pisani P., Parkin D.M., Munoz N., and Ferlay J. Cancer and infection: estimates of the attributable fraction in 1990. Cancer Epidemiol Biomarkers Prev 6 (1997) 387-400
25. Tsai J.F., Jeng J.E., Ho M.S., Chang W.Y., Hsieh M.Y., Lin Z.Y., et al. Additive effect modification of hepatitis B surface antigen and e antigen on the development of hepatocellular carcinoma. Br J Cancer 73 (1996) 1498-1502
26. Sun C.A., Farzadegan H., You S.L., Lu S.N., Wu M.H., Wolfe L., et al. Mutual confounding and interactive effects between hepatitis C and hepatitis B viral infections in hepatocellular carcinogenesis: a population-based case-control study in Taiwan. Cancer Epidemiol Biomarkers Prev 5 (1996) 173-178
27. Aggarwal R., Ghoshal U.C., and Naik S.R. Assessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model. J Hepatol 38 (2003) 215-222
28. Griffiths U.K., Hutton G., and Das Dores Pascoal E. The cost-effectiveness of introducing hepatitis B vaccine into infant immunization services in Mozambique. Health Policy Plann 20 (2005) 50-59
29. Khan M.M., and Ehreth J. Costs and benefits of polio eradication: a long-run global perspective. Vaccine 21 (2003) 702-705
30. Hsu H.Y., Chang M.H., Chen D.S., Lee C.Y., and Sung J.L. Baseline seroepidemiology of hepatitis B virus infection in children in Taipei, 1984, a study just before mass hepatitis B vaccination program in Taiwan. J Med Virol 18 (1986) 301-307
31. McMahon B.J., Alward W.L., Hall D.B., Heyward W.L., Bender T.R., Francis D.P., et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 151 (1985) 599-603
32. Shah N., Ostrow D., Altman N., and Baker A.L. Evolution of acute hepatitis B in homosexual men to chronic hepatitis B. Prospective study of placebo recipients in a hepatitis B vaccine trial. Arch Intern Med 145 (1985) 881-882
33. Tassopoulos N.C., Papaevangelou G.J., Sjogren M.H., Roumeliotou-Karayannis A., Gerin J.L., and Purcell R.H. Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults. Gastroenterology 92 (1987) 1844-1850
34. Dupuy J.M., Frommel D., and Alagille D. Severe viral hepatitis type B in infancy. Lancet 25 (1975) 191-194
35. Redeker A.G. Viral hepatitis: clinical aspects. Am J Med Sci 270 (1975) 9-16
36. Karvountzis G.G., Redeker A.G., and Peters R.L. Long term follow-up studies of patients surviving fulminant viral hepatitis. Gastroenterology 67 (1974) 870-877
37. McMahon B.J., Alberts S.R., Wainwright R.B., Bulkow L., and Lanier A.P. Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. Arch Intern Med 150 (1990) 1051-1054
38. Kocak N., Ozen H., Yuce A., and Gurakan F. Long-term follow-up of hepatitis B virus carriers with normal transaminases levels. Turk J Pediatr 40 (1998) 365-372
39. Nishida S., Tada R., Nishiwaki T., Takahashi R., Yanagawa S., and Mitamura K. Seven-year follow-up studies on asymptomatic HBs Ag carriers. Sangyo Igaku - Jpn J Ind Health 24 (1982) 253-264
40. Yu M.W., Hsu F.C., Sheen I.S., Chu C.M., Lin D.Y., Chen C.J., et al. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol 145 (1997) 1039-1047
41. McMahon B.J., Holck P., Bulkow L., and Snowball M. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med 135 (2001) 759-768
42. Alward W.L., McMahon B.J., Hall D.B., Heyward W.L., Francis D.P., and Bender T.R. The long-term serological course of asymptomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma. J Infect Dis 151 (1985) 604-609
43. Sherman M., Peltekian K.M., and Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 30 1 (1995) 257-264
44. Sherman M., Peltekian K.M., and Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 22 (1995) 432-438
45. Liaw Y.F., Sheen I.S., Chen T.J., Chu C.M., and Pao C.C. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology 30 (1991) 257-264
46. Liaw Y.F., Sheen I.S., Chen T.J., Chu C.M., and Pao C.C. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology 13 (1991) 627-631
47. Crook P.D., Jones M.E., and Hall A.J. Mortality of hepatitis B surface antigen-positive blood donors in England and Wales. Int J Epidemiol 32 (2003) 118-124
48. Liaw Y.F., Tai D.I., Chu C.M., and Chen T.J. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 30 1 (1988) 257-264
49. Liaw Y.F., Tai D.I., Chu C.M., and Chen T.J. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 8 (1988) 493-496
50. Fattovich G., Brollo L., Giustina G., Noventa F., Pontisso P., Alberti A., et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 32 (1991) 294-298
51. Ikeda K., Saitoh S., Suzuki Y., Kobayashi M., Tsubota A., Koida I., et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 28 (1998) 930-938
52. DS. C, JC. S, JL. S. A prospective study on the occurrence of hepatocellular carcinoma in patients with cirrhosis, chronic hepatitis and asymptomatic HBsAg carriers. Abstracts of Papers Presented at Symposium on Epidemiology and Clinical Trials 1985 June (10-12): 1036-1049.
53. De Groote J., Fevery J., and Lepoutre L. Long-term follow-up of chronic active hepatitis of moderate severity. Gut 19 (1978) 510-513
54. Lo K.J., Tong M.J., Chien M.C., Tsai Y.T., Liaw Y.F., Yang K.C., et al. The natural course of hepatitis B surface antigen-positive chronic active hepatitis in Taiwan. J Infect Dis 146 (1982) 205-210
55. Liaw Y.F., Tai D.I., Chu C.M., Lin D.Y., Sheen I.S., Chen T.J., et al. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study. Gastroenterology 90 (1986) 263-267
56. Fattovich G., Giustina G., Schalm S.W., Hadziyannis S., Sanchez-Tapias J., Almasio P., et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP study group on hepatitis B virus and cirrhosis. Hepatology 30 1 (1995) 257-264
57. Fattovich G., Giustina G., Schalm S.W., Hadziyannis S., Sanchez-Tapias J., Almasio P., et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP study group on hepatitis B virus and cirrhosis. Hepatology 21 (1995) 77-82
58. D'Amico G., Morabito A., Pagliaro L., and Marubini E. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci 31 (1986) 468-475
59. Fattovich G. Natural history and prognosis of hepatitis B. Semin Liver Dis 23 (2003) 47-58
60. Marcellin P., Castelnau C., Martinot-Peignoux M., and Boyer N. Natural history of hepatitis B. Minerva Gastroenterol Dietol 51 (2005) 63-75
61. McMahon B.J., Bulkow L., Harpster A., Snowball M., Lanier A., Sacco F., et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology 30 (2000) 257-264
62. McMahon B.J., Bulkow L., Harpster A., Snowball M., Lanier A., Sacco F., et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology 32 (2000) 842-846
63. Ganzinger U., Badelt C., Vass K., Strasser-Fuchs S., Fazekas F., Berger T., et al. Health care costs of multiple sclerosis in Austria. Cross-sectional study including consideration of quality of life. Nervenarzt 75 (2004) 1000-1006
64. Bloom B.S., Hillman A.L., Fendrick A.M., and Schwartz J.S. A reappraisal of hepatitis B virus vaccination strategies using cost-effectiveness analysis.[see comment]. Ann Intern Med 118 (1993) 298-306
65. Fendrick A.M., Lee J.H., LaBarge C., and Glick H.A. Clinical and economic impact of a combination Haemophilus influenzae and Hepatitis B vaccine: estimating cost-effectiveness using decision analysis. Arch Pediatr Adolesc Med 153 (1999) 126-136
66. Ginsberg G.M., and Shouval D. Cost-benefit analysis of a nationwide neonatal inoculation programme against hepatitis B in an area of intermediate endemicity. J Epidemiol Commun Health 46 (1992) 587-594
67. Da Villa G., and Sepe A. Immunization programme against hepatitis B virus infection in Italy: cost-effectiveness. Vaccine 17 (1999) 1734-1738